Skip to main content

Advertisement

SpringerLink
Log in

Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Clinical differences between anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALK− ALCL) and peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), remain unclear. The aim of this study was to compare the clinical and prognostic features of these two lymphoma types. We retrospectively analyzed 167 patients with ALK− ALCL (n = 48) and PTCL-NOS (n = 119). Compared with ALK− ALCL patients, PTCL-NOS patients exhibited distinct differences in clinical features with a propensity for more advanced stages, frequent extranodal involvement, and a poor performance status, leading to a higher risk group according to the International Prognostic Index or Prognostic Index for PTCL-NOS. Patients with ALK− ALCL were associated with a higher complete response rate (47.9 vs. 31.0 %; P = 0.041) after initial chemotherapy than patients with PTCL-NOS. The prognosis was significantly different between two subtypes, with a 5-year overall survival (OS) rate of 57.9 % for ALK− ALCL and 23.9 % for PTCL-NOS (P = 0.002). The subgroup analysis showed significant differences in OS and progression-free survival between the two subtypes in early-stage diseases, but not in advanced-stage diseases. We conclude that patients with ALK− ALCL showed favorable clinical features, higher chemosensitivity, and a superior outcome than those with PTCL-NOS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:265–276

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Anderson JR, Armitage JO, Weisenburger DD (1998) Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 9:717–720

    Article  CAS  PubMed  Google Scholar 

  3. Vose J, Armitage J, Weisenburger D, on behalf of International T-cell Lymphoma Project (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130

    Article  PubMed  Google Scholar 

  4. Arora N, Manipadam MT, Nair S (2013) Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma 54:1004–1011

    Article  PubMed  Google Scholar 

  5. Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, Bi CF, Zuo Z, Wang XQ, Huang J, Dai L, Liu WP (2011) Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol 6:77

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, Tomotaka S, Morton LM, Weisenburger DD, Matsuo K (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164:536–545

    Article  PubMed  Google Scholar 

  7. Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848–858

    CAS  PubMed  Google Scholar 

  8. Swerdllow S, Campo E, Harris NL (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, France

    Google Scholar 

  9. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD (2008) ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK-ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496–5504

    Article  CAS  PubMed  Google Scholar 

  10. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418–3425

    Article  CAS  PubMed  Google Scholar 

  11. Sibon D, Fournier M, Briere J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 30:3939–3946

    Article  PubMed  Google Scholar 

  12. Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, Mori N, Kojima M, Yoshino T, Yamabe H, Shiota M, Mori S, Ogura M, Hamajima N, Seto M, Suchi T, Morishima Y, Nakamura S (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993–3000

    CAS  PubMed  Google Scholar 

  13. ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJ (2003) ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43:462–469

    Article  PubMed  Google Scholar 

  14. Medeiros LJ, Elenitoba-Johnson KS (2007) Anaplastic Large Cell Lymphoma. Am J Clin Pathol 127:707–722

    Article  PubMed  Google Scholar 

  15. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ (2003) ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review. J Pathol 200:4–15

    Article  PubMed  Google Scholar 

  16. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915–2923

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F, Sabattini E, Agostinelli C, Gazzola A, Laginestra MA, Mannu C, Sapienza MR, Hartmann S, Hansmann ML, Piva R, Iqbal J, Chan JC, Weisenburger D, Vose JM, Bellei M, Federico M, Inghirami G, Zinzani PL, Pileri SA (2013) Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol 31:3019–3025

    Article  PubMed  Google Scholar 

  18. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM (2014) Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25:2211–2217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zettl A, Rudiger T, Konrad MA, Chott A, Simonitsch-Klupp I, Sonnen R, Muller-Hermelink HK, Ott G (2004) Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 164:1837–1848

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, Ponzoni M, Zamo A, Iqbal J, Piccaluga PP, Neri A, Chan WC, Pileri S, Bertoni F, Inghirami G, Piva R, European TCLSG (2012) Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 120:1274–1281

    Article  CAS  PubMed  Google Scholar 

  21. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, Kurtin PJ, Dogan A (2009) Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 23:574–580

    Article  CAS  PubMed  Google Scholar 

  22. Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, Porcher JC, Ozsan N, Wieben ED, Eckloff BW, Vasmatzis G (2011) Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 117:915–919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, Fornari A, Martinoglio B, Medico E, Zamo A, Facchetti F, Ponzoni M, Geissinger E, Rosenwald A, Muller-Hermelink HK, De Wolf-Peeters C, Piccaluga PP, Pileri S, Neri A, Inghirami G (2010) Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 28:1583–1590

    Article  CAS  PubMed  Google Scholar 

  24. Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR, Ludkovski O, Savage KJ, Armitage JO, Sanger WG (2008) Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol 141:461–469

    Article  CAS  PubMed  Google Scholar 

  25. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, Lim MS, Piva R, Barreca A, Pellegrino E, Spaccarotella E, Lachel CM, Kucuk C, Jiang CS, Hu X, Bhagavathi S, Greiner TC, Weisenburger DD, Aoun P, Perkins SL, McKeithan TW, Inghirami G, Chan WC (2013) MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood 122:2083–2092

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473–1480

    Article  PubMed  PubMed Central  Google Scholar 

  27. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood

  28. Asano N, Suzuki R, Ohshima K, Kagami Y, Ishida F, Yoshino T, Ogawa H, Morishima Y, Nakamura S (2010) Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. Int J Hematol 91:426–435

    Article  CAS  PubMed  Google Scholar 

  29. Mason DY, Harris NL, Delsol G et al (2008) Anaplastic large cell lymphoma (ALCL), ALK-negative. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization Classification of Tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 317–319

    Google Scholar 

  30. Pileri SA, Weisenburger DD, Sng I et al (2008) Peripheral T-cell lymphoma, not otherwise specified. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization Classification of Tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 306–308

    Google Scholar 

  31. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, Lu N, Yu ZH (2006) Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181–189

    Article  PubMed  Google Scholar 

  32. Zhang XM, Li YX, Wang WH, Jin J, Wang SL, Liu YP, Song YW, Fang H, Ren H, Zhou LQ, Liu XF, Yu ZH (2013) Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified. Int J Radiat Oncol Biol Phys 85:1051–1056

    Article  PubMed  Google Scholar 

  33. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253

    CAS  PubMed  Google Scholar 

  34. International Peripheral T-cell Lymphoma Progect (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402–3408

    Article  Google Scholar 

  35. Intergruppo Italiano Linfomi (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479

    Article  Google Scholar 

  36. Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N, Ghita G, Martinez-Trillos A, Colomo L, Setoain X, Rodriguez S, Gine E, Campo E, Lopez-Guillermo A (2011) Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 22:397–404

    Article  CAS  PubMed  Google Scholar 

  37. Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS (2009) Clinical features and prognostic factors of patients with “peripheral T cell lymphoma, unspecified”. Ann Hematol 88:111–119

    Article  PubMed  Google Scholar 

  38. Xu P, Yu D, Wang L, Shen Y, Shen Z, Zhao W (2015) Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients. Ann Hematol 94:239–247

    Article  CAS  PubMed  Google Scholar 

  39. Peng Y, Huang H, Zhou Z, Lin X, Pang Z, Guan Z (2006) Clinical outcome of 117 patients with peripheral T-cell lymphomas, unspecified. China Oncol 16:132–135

    Google Scholar 

  40. Cen H, Hu XH, Zhou WX, Tan XH, Lu YK (2007) Clinical characteristics and treatment response of 163 patients with peripheral T-cell lymphoma unspecified. Chin J Clin Oncol 17:982–985

    Google Scholar 

  41. Asano N, Suzuki R, Kagami Y, Ishida F, Kitamura K, Fukutani H, Morishima Y, Takeuchi K, Nakamura S (2005) Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29:1284–1293

    Article  PubMed  Google Scholar 

  42. Rodriguez-Antona C, Leskela S, Zajac M, Cuadros M, Alves J, Moneo MV, Martin C, Cigudosa JC, Carnero A, Robledo M, Benitez J, Martinez-Delgado B (2007) Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood 110:3345–3351

    Article  CAS  PubMed  Google Scholar 

  43. Pescarmona E, Pignoloni P, Puopolo M, Martelli M, Addesso M, Guglielmi C, Baroni CD (2001) p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol 195:361–366

    Article  CAS  PubMed  Google Scholar 

  44. Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S, Went P, Klein U, Zinzani PL, Baccarani M, Dalla Favera R, Pileri SA (2007) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117:823–834

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM, Wu JX, Wang W, Wu T, Lu B, Zhu SY, Qian LT, Zhang FQ, Hou XR, Liu QF, Li YX (2015) Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia 29:1571–1577

    Article  CAS  PubMed  Google Scholar 

  46. Qi SN, Li YX, Wang H, Wang WH, Jin J, Song YW, Wang SL, Liu YP, Zhou LQ, Yu ZH (2009) Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation. Cancer 115:4980–4989

    Article  PubMed  Google Scholar 

  47. Yang Y, Zhu Y, Cao JZ, Zhang YJ, Yuan ZY, Xu LM, Wu JX, Wang W, Wu T, Lu B, Zhu SY, Qian LT, Zhang FQ, Hou XR, Liu QF, Li YX (2015) Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood 126:1424–1432

    Article  CAS  PubMed  Google Scholar 

  48. Zhang XM, Li YX, Wang WH, Jin J, Wang SL, Liu YP, Song YW, Ren H, Fang H, Zhou LQ, Chen B, Qi SN, Liu QF, Lu NN, Liu XF, Yu ZH (2013) Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma. Eur J Haematol 90:195–201

    Article  CAS  PubMed  Google Scholar 

Download references

Author contribution

Y.X.L. designed the research, analyzed the data, and wrote the paper; X.W.D. analyzed the data and wrote the paper. All authors provided study materials or patients and approved the paper.

Author information

Author notes

  1. Xi-Mei Zhang

    Present address: Cancer Hospital, Tianjin Medical University, Tianjin, People’s Republic of China

Authors and Affiliations

  1. Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People’s Republic of China

    Xiu-Wen Deng, Xi-Mei Zhang, Wei-Hu Wang, Shu-Lian Wang, Jing Jin, Hui Fang, Hua Ren, Yue-Ping Liu, Yong-Wen Song & Ye-Xiong Li

  2. Medical Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People’s Republic of China

    Xiao-Hui He & Mei Dong

Authors
  1. Xiu-Wen Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xi-Mei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei-Hu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shu-Lian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hui Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hua Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yue-Ping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiao-Hui He
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mei Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yong-Wen Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ye-Xiong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ye-Xiong Li.

Ethics declarations

This is a retrospective study, and all patients provided informed consent for the collection of medical information at their first medical visit. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards..

Funding

None.

Conflict of interest

The authors declare no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplemental Table 1

(DOC 63 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deng, XW., Zhang, XM., Wang, WH. et al. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. Ann Hematol 95, 1271–1280 (2016). https://doi.org/10.1007/s00277-016-2696-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2696-9

Keywords

Search

Navigation